Silo Pharma, Inc.

Contributing Author

Recent Articles by Silo Pharma, Inc.

May-07	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury SILO GlobeNewswire
Apr-29	Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD SILO GlobeNewswire
Apr-22	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents SILO -16.85% SILO -8.13% GlobeNewswire
Apr-20	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics SILO +29.34% GlobeNewswire
Apr-06	Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy SILO +49.02% SILO GlobeNewswire
Feb-23	Silo Pharma Announces Share Buyback Program SILO +24.00% SILO GlobeNewswire
Feb-18	Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio SILO GlobeNewswire
Dec-30	Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 SILO GlobeNewswire
Nov-17	Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD SILO GlobeNewswire
Oct-29	Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain SILO GlobeNewswire
Oct-23	Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program SILO GlobeNewswire
Oct-08	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth SILO GlobeNewswire
Oct-06	Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) SILO GlobeNewswire
Oct-01	Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SILO GlobeNewswire
Sep-30	Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SILO -7.95% GlobeNewswire
Sep-29	Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management SILO GlobeNewswire
Sep-23	Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security SILO GlobeNewswire
Sep-16	Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy SILO -9.27% GlobeNewswire
Sep-09	Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug SILO +9.19% GlobeNewswire
Sep-03	Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio SILO GlobeNewswire
Aug-21	Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal SILO -5.45% SILO GlobeNewswire
Aug-19	Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway SILO -6.54% GlobeNewswire
Aug-05	Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform SILO -17.57% GlobeNewswire
Jul-16	Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 SILO GlobeNewswire
Jul-07	Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 SILO GlobeNewswire
Jun-25	Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market SILO GlobeNewswire
Jun-11	Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears SILO GlobeNewswire
Jun-05	Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset SILO +12.08% GlobeNewswire
May-21	Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 SILO -8.84% GlobeNewswire
May-16	Silo Pharma Announces Closing of $2 Million Public Offering SILO -7.04% GlobeNewswire
May-15	Silo Pharma Announces Pricing of $2 Million Public Offering SILO -37.81% GlobeNewswire
May-14	Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 SILO -24.00% GlobeNewswire
May-14	Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories SILO -24.00% GlobeNewswire

Silo Pharma, Inc.

Recent Articles by Silo Pharma, Inc.

Upgrade your Finviz experience